Licensing and Other Arrangements - Novartis - NIS793 (Details) $ in Thousands |
3 Months Ended | 12 Months Ended | ||||||
|---|---|---|---|---|---|---|---|---|
|
Oct. 20, 2021
USD ($)
|
Oct. 21, 2020
USD ($)
|
Sep. 30, 2015
USD ($)
item
|
Mar. 31, 2022
USD ($)
|
Mar. 31, 2021
USD ($)
|
Dec. 31, 2017
USD ($)
|
Dec. 31, 2015
USD ($)
|
Dec. 31, 2021
USD ($)
|
|
| Licensing and other arrangements | ||||||||
| Revenue from contracts with customers | $ 2,750 | $ 19 | ||||||
| Novartis Note | ||||||||
| Licensing and other arrangements | ||||||||
| Reduction in debt obligation | $ 7,300 | |||||||
| Novartis International | License Agreement | ||||||||
| Licensing and other arrangements | ||||||||
| Agreement termination prior written notice period | 180 days | |||||||
| Number of performance obligations | item | 1 | |||||||
| Cash payment received | 17,700 | $ 37,000 | ||||||
| Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones | $ 410,000 | $ 480,000 | ||||||
| Revenue from contracts with customers | $ 35,000 | $ 25,000 | 0 | $ 0 | $ 10,000 | |||
| Royalty payment period | 10 years | |||||||
| Contract assets | 0 | $ 0 | ||||||
| Contract liabilities | 0 | 0 | ||||||
| Capitalized contract costs | $ 0 | $ 0 | ||||||
| X | ||||||||||
- Definition Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Net increase or decrease in the carrying amount of the debt instrument for the period. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Agreement termination prior written notice period, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days No definition available.
|
| X | ||||||||||
- Definition Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones. May also include potential payments for achievement of clinical milestones. No definition available.
|
| X | ||||||||||
- Definition Number of performance obligations. No definition available.
|
| X | ||||||||||
- Definition Cash proceeds received under agreement. May include, but is not limited to, upfront payments, one-time payments and cash-portion of payments received. No definition available.
|
| X | ||||||||||
- Definition Minimum period over which counterparty is obligated to pay royalties under terms of agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|